The study of 99mTc-radiolabeled peptide for breast cancer imaging

A Phase III clinical study of 99mTc-labeled peptide for imaging and HER2 assessment in patients with breast cancer

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141006019423N3

Enrollment

250

Registered

2024-05-25

Start date

2024-08-22

Completion date

Unknown

Last updated

2024-05-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer. Malignant neoplasm of breast of unspecified site, female

Interventions

Intervention group: Imaging at 1,2,3 and 4 hours after the intravenous injection of 740 MBq of radiopeptide.

Eligibility

Sex/Gender

Female

Age

20 Years to No maximum

Inclusion criteria

Inclusion criteria: Female breast cancer Without biopsy history

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Radiotracer uptake by breast cancer. Timepoint: Imaging of the breast at 1,2,3 and 4 hours after the administration of the radiolabeled peptide. Method of measurement: Imaging.;Distribution of radiolabeled peptide in other tissues. Timepoint: Imaging at 1,2,3 and 4 hours after the administration of the radiolabeled peptide. Method of measurement: Imaging.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr. Seyed Jalal Hosseinimehr

Mazandaran University of Medical Sciences

sjhosseinim@yahoo.com+98 11 3354 4308

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026